File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

TitleComparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study
Authors
KeywordsCOVID-19
Myocarditis
Myopericarditis
Pericarditis
Vaccine
Issue Date2022
Citation
Clinical Research in Cardiology, 2022, v. 111, n. 10, p. 1098-1103 How to Cite?
AbstractBackground: Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods: This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results: This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127–838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1–7.4) with a rate ratio of 55.0 (95% CI 21.4–141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1–7.4) with a rate ratio of 0.93 (95% CI 0.69–1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions: COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis. Graphical abstract: [Figure not available: see fulltext.].
Persistent Identifierhttp://hdl.handle.net/10722/330784
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.416
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChou, Oscar Hou In-
dc.contributor.authorZhou, Jiandong-
dc.contributor.authorLee, Teddy Tai Loy-
dc.contributor.authorKot, Thompson-
dc.contributor.authorLee, Sharen-
dc.contributor.authorWai, Abraham Ka Chung-
dc.contributor.authorWong, Wing Tak-
dc.contributor.authorZhang, Qingpeng-
dc.contributor.authorCheng, Shuk Han-
dc.contributor.authorLiu, Tong-
dc.contributor.authorVassiliou, Vassilios S.-
dc.contributor.authorCheung, Bernard Man Yung-
dc.contributor.authorTse, Gary-
dc.date.accessioned2023-09-05T12:14:15Z-
dc.date.available2023-09-05T12:14:15Z-
dc.date.issued2022-
dc.identifier.citationClinical Research in Cardiology, 2022, v. 111, n. 10, p. 1098-1103-
dc.identifier.issn1861-0684-
dc.identifier.urihttp://hdl.handle.net/10722/330784-
dc.description.abstractBackground: Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods: This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results: This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127–838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1–7.4) with a rate ratio of 55.0 (95% CI 21.4–141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1–7.4) with a rate ratio of 0.93 (95% CI 0.69–1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions: COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis. Graphical abstract: [Figure not available: see fulltext.].-
dc.languageeng-
dc.relation.ispartofClinical Research in Cardiology-
dc.subjectCOVID-19-
dc.subjectMyocarditis-
dc.subjectMyopericarditis-
dc.subjectPericarditis-
dc.subjectVaccine-
dc.titleComparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00392-022-02007-0-
dc.identifier.pmid35333945-
dc.identifier.scopuseid_2-s2.0-85127516840-
dc.identifier.volume111-
dc.identifier.issue10-
dc.identifier.spage1098-
dc.identifier.epage1103-
dc.identifier.eissn1861-0692-
dc.identifier.isiWOS:000773171300001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats